MONTREAL, Jan. 29 /PRNewswire-FirstCall/ - CryoCath Technologies , the global leader in cryotherapy products to treat cardiovascular disease, today announced the appointment of Jan Keltjens as President and CEO, effective March 1, 2007.
“Jan’s substantial experience in managing product development, manufacturing and world-wide sales and marketing experience will enable him to guide CryoCath through its next phase of growth,” said Henri Vienneau, Interim CEO and Chairman of the Board of Directors. “As incoming President and CEO, his priority will be to focus the company on driving commercialization and ramping up manufacturing of Arctic Front in Europe and advancing our pivotal STOP AF trial in the United States.”
Mr. Keltjen’s professional achievements to date are substantial. He joined Cordis in 1995 as Vice-President and Managing Director of Cordis Europe, in which role he provided leadership to international Operations and R&D. Following this, Jan rose through the ranks, via various successful assignments, to his current position of World-wide General Manager of Cordis Neurovascular Inc., which he has held since 2000. There, he held full profit and loss responsibility for this fast growing business. In this role, he provided leadership to sales, global marketing, operations, finance, R&D, QA, RA, CR and HR. During his tenure, this innovation driven business, had grown in sales multiple times both in the US and worldwide, and had become one of the fastest growing businesses within the Johnson & Johnson Medical Device group of companies. Prior to joining Cordis, Mr. Keltjens held progressively senior roles at Priva Group and Unilever. He holds a Masters in Physics with a specialty in low temperature physics from The University of Eindhoven in The Netherlands.
“Cryotherapy for the treatment of Atrial Fibrillation is the type of innovation that drives high growth in the medical device industry. Moreover, I believe Arctic Front represents an unparalleled opportunity, for both the medical community and CryoCath,” said Jan Keltjens. “As such, I look forward to applying my skill set and years of experience developing, manufacturing and commercializing products to advancing CryoCath’s unique value proposition.”
About CryoCath
CryoCath - www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiovascular disease. With a priority focus on providing physicians with a complete solution of catheter and surgical products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.
This press release includes “forward-looking statements” that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath’s annual report available at www.sedar.com under the heading Risks and Uncertainties in the Management’s Discussion and Analysis section.
CryoCath Technologies Inc.
CONTACT: visit our website at www.cryocath.com, or contact Michael Moore,Investor Relations, Phone: (416) 815-0700 ext. 241, Fax : (416) 815-0080,E-mail: mmoore@equicomgroup.com
